ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > VEGF165 > VE5-H8210

Biotinylated Human VEGF165 Protein, epitope tag free, ultra sensitivity, primary amine labeling

INTRODUCTION
QC & Assay Protocol
Citation & Background
  • Synonym
    RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
  • Source
    Biotinylated Human VEGF165, epitope tag free, primary amine labeling(VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
    Predicted N-terminus: Ala 27
    Request for sequence
  • Molecular Characterization
    VEGF165 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 25-28 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling
    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 24 months under sterile conditions after reconstitution.
SDS-PAGE
VEGF165 SDS-PAGE

Biotinylated Human VEGF165, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

Bioactivity-ELISA
VEGF165 ELISA

Immobilized Human VEGFR1/R2, Fc Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.1-1 ng/mL (QC tested).

Protocol
VEGF165 ELISA

Immobilized Anti-VEGF MAb, Human IgG1 (Avastin) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.03-1 ng/mL (Routinely tested).

Protocol
VEGF165 ELISA

Immobilized Human Neuropilin-1, His Tag (Cat. No. NR1-H5228) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, epitope tag free, primary amine labeling (Cat. No. VE5-H8210) with a linear range of 0.005-0.625 μg/mL (Routinely tested).

Protocol
  • Background
    VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 70,000

価格(JPY) : 274,400

Bulk Inquiry 製品のカスタマイズ
人気商品のおすすめ
ストレプトアビジンコートプレート

価格(JPY) : 8,960

価格(JPY) : 38,360

ストレプトアビジン-HRP

価格(JPY) : 14,000

価格(JPY) : 33,600

Magnetic Beads™ 磁気ビーズ

価格(JPY) : 38,640

価格(JPY) : 64,400

一括購入 製品のカスタマイズ

Antibody Licensing

more

プロモーション＆展示



医薬品開発状況

  • Number of Launched Drugs：40 Details
  • Number of Drugs in Clinical Trials：63 Details
  • Latest Research Phase：Approved
ほかの製品について

データシート＆ドキュメンテーション

DMF請求
DMF (Drug Master File)

お問い合わせ

+1  800-810-0816 (US)
+86 400-682-2521 (AP)
全ての代理店を表示する

関連製品一覧

新製品

お問い合わせ＆コメント

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap